Opioid Related Disorder Clinical Trial Pipeline Expands as 10+ Companies Race to Redefine Glaucoma Treatment Landscape | DelveInsight

(Albany, US) On November 10, 2026, DelveInsight’s “Opioid Use Disorder Pipeline Insight 2026” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Opioid Use Disorder pipeline landscape. It covers the Opioid Use Disorder pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Opioid Use Disorder pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Opioid Use Disorder Pipeline? @ https://www.delveinsight.com/sample-request/opioid-related-disorder-pipeline-insight

Key Takeaways from the Opioid Use Disorder Pipeline Report

• On November 07, 2026 – Milton S. Hershey Medical Center updated its clinical trial information for an ongoing study evaluating semaglutide, a GLP-1 receptor agonist, in adults with opioid use disorder receiving buprenorphine or methadone maintenance therapy. The Phase II study aims to investigate whether semaglutide can reduce illicit opioid use and improve treatment outcomes.
• On November 04, 2026 – Eli Lilly and Company updated the recruitment information for its Phase II RENEW-Op-1 clinical trial evaluating brenipatide (LY3537031) as an adjunctive treatment to buprenorphine, with or without naloxone, in patients with opioid use disorder. The trial expanded its recruitment network to 68 study locations across the United States, United Kingdom, and Canada.
• On October 23, 2026, Adneuris Therapeutics updated its clinical trial registration for an investigational study evaluating cebranopadol in adults with chronic pain who are physically dependent on opioids. The study aims to assess the ability of cebranopadol to suppress opioid withdrawal signs and symptoms.
• DelveInsight’s Opioid Use Disorder Pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Opioid Use Disorder treatment.
• The leading Opioid Use Disorder Companies include GW Pharmaceuticals, Opiant Pharmaceuticals, Trevi Therapeutics, Aphios, Astellas Pharma, and others.
• Promising Opioid Use Disorder Therapies include XR-NTX, Methadone, Buprenorphine (BUP), INDV-2000, Lofexidine 0.18 MG, NTX/BUP, Naltrexone, CAM203, and others.

Want to know which companies are leading innovation in Opioid Use Disorder? @ Opioid Use Disorder Clinical Trials Assessment

The Opioid Use Disorder Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Opioid Use Disorder Pipeline Report also highlights the unmet needs with respect to the Opioid Use Disorder.

Opioid Use Disorder Overview

Opioid Use Disorder (OUD) is a chronic, relapsing medical condition marked by a problematic pattern of opioid use that causes significant distress or impairment in daily life. Opioids include prescription pain relievers such as oxycodone and hydrocodone, as well as illicit drugs such as heroin and illicitly manufactured fentanyl. Regular use can lead to tolerance, dependence and withdrawal symptoms, and in OUD these effects combine with strong cravings and a loss of control over use. Clinicians diagnose the condition using criteria in the DSM-5, which grades it as mild, moderate or severe based on the number of symptoms present.

Opioid Use Disorder Emerging Drugs Profile

• ASP8062: Astellas Pharma

Astellas Pharma’s lead drug candidate, ASP8062, is an analgesic class drug. It is an orally active γ-amino-butyric acid type B (GABAB) receptor positive allosteric modulator currently in phase II development. Phase 2 data demonstrated that ASP8062 for the treatment of Opioid Related Disorder as well as pain has beneficial effects. It was safe and well tolerated by the healthy subjects. It enhances the GABAergic transmission mediated by GABAB receptors by increasing the potency of endogenous agonist without overstimulating the receptor.

• OPNT-003 (Intranasal Nalmefene): Opiant Pharmaceuticals

Opiant Pharmaceuticals “breakthrough” drug OPNT-003 is a long lasting opioid antagonist for the treatment of Opioid overdose and has demonstrated positive data from its phase I trials.

If you’re tracking ongoing Opioid Use Disorder Clinical trials @ Opioid Use Disorder Treatment Drugs

The Opioid Use Disorder Pipeline report provides insights into:-

• The report provides detailed insights about companies that are developing therapies for the treatment of Opioid Use Disorder with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Opioid Use Disorder Treatment.
• Opioid Use Disorder Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Opioid Use Disorder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Opioid Use Disorder market.

Opioid Use Disorder Companies

GW Pharmaceuticals, Opiant Pharmaceuticals, Trevi Therapeutics, Aphios, Astellas Pharma, and others

Opioid Use Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Subcutaneous
• Intravenous
• Oral
• Intramuscular
• Molecule Type

Opioid Use Disorder Products have been categorized under various Molecule types such as

• Small molecules
• Natural metabolites
• Monoclonal antibodies
• Product Type

From emerging drug candidates to competitive intelligence, the Opioid Use Disorder Pipeline Report @ Opioid Use Disorder Market Drivers and Barriers, and Future Perspectives

Scope of the Opioid Use Disorder Pipeline Report

• Coverage- Global
• Opioid Use Disorder Companies- GW Pharmaceuticals, Opiant Pharmaceuticals, Trevi Therapeutics, Aphios, Astellas Pharma, and others.
• Promising Opioid Use Disorder Therapies- XR-NTX, Methadone, Buprenorphine (BUP), INDV-2000, Lofexidine 0.18 MG, NTX/BUP, Naltrexone, CAM2038 and others.
• Opioid Use Disorder Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Opioid Use Disorder Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what’s next for the Opioid Use Disorder Treatment landscape in this detailed analysis @ Opioid Use Disorder Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. Opioid Related Disorder: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Opioid Related Disorder – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Opioid Related Disorder Collaboration Deals
9. Mid Stage Products (Phase II)
10. ASP8062: Astellas Pharma
11. Drug profiles in the detailed report…..
12. Early Stage Products (Phase I)
13. OPNT-003: Opiant Pharmaceuticals
14. Drug profiles in the detailed report…..
15. Pre-clinical and Discovery Stage Products
16. Drug profiles in the detailed report…..
17. Inactive Products
18. Opioid Related Disorder Key Companies
19. Opioid Related Disorder Key Products
20. Opioid Related Disorder Unmet Needs
21. Opioid Related Disorder Market Drivers and Barriers
22. Opioid Related Disorder Future Perspectives and Conclusion
23. Opioid Related Disorder Analyst Views
24. Opioid Related Disorder Key Companies
25. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/opioid-related-disorder-pipeline-insight